文献速递浆细胞疾病

日本中枢神经系统多发性骨髓瘤全国调查:影响生存的预后与治疗因素分析

A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival.
PubMed 文献 · Br J Haematol · 2021-07-28

在60例接受治疗的患者中,多因素分析显示来那度胺、鞘内化疗和放疗与更长OS相关,并据此建立评分系统分层OS。

要点

  • CNS-MM约占MM的1%,初诊即诊断者OS长于复发时诊断者。
  • 来那度胺、鞘内化疗和放疗是多因素分析中与更长OS相关的治疗因素。
  • 基于来那度胺、鞘内化疗和放疗数量的评分系统可分层CNS-MM患者的OS。

核心结论

  • 包含来那度胺联合常规鞘内化疗和放疗的多模式治疗可改善CNS-MM患者的总生存。

研究设计与样本

  • 日本全国多中心回顾性研究,纳入2005至2016年77例成人CNS-MM患者。
  • 在60例接受任何治疗的患者中比较复发型MM伴CNS-MM,并进行多因素分析。

临床怎么用

  • 对CNS-MM患者可考虑包含来那度胺、鞘内化疗和放疗的多模式治疗以改善生存。
  • 可利用来那度胺、鞘内化疗和放疗数量构成的评分系统进行预后分层。

局限性

  • 本研究为回顾性研究,样本量较小(77例),初诊时诊断CNS-MM者仅3例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This nationwide multicentre retrospective study was performed to analyze clinical features that predict the prognosis of central nervous system invasion in multiple myeloma (CNS-MM, approximately 1% of MM). Overall, of the 77 adult patients with CNS-MM identified between 2005 and 2016, those diagnosed at MM diagnosis (n = 3) had longer overall survival (OS) than those diagnosed at relapse (n = 74; median: 48·5 vs 2·7 months). Therefore, we compared the relapsed MM with CNS-MM in patients with any treatment (n = 60). Multivariate analyses revealed that lenalidomide treatment [hazard ratio (HR) 0·27, P = 0·003], intrathecal chemotherapy (IT; HR 0·54, P = 0·05), and radiation therapy (RTx; HR 0·33, P < 0·001) for CNS-MM had a positive effect on longer OS. These factors were used to develop a scoring system combining the number of treatments with lenalidomide, IT, and RTx (0, 1, 2, 3). The OS of CNS-MM patients was stratified based on these factors, with a median OS of 1·1, 4·5, and 7·5 months for patients with zero, one, two to three favourable features, respectively (0 vs 1, P = 0·0002; 1 vs 2-3, P = 0·08). Multimodal treatment including lenalidomide in addition to conventional IT and RTx can improve OS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yamashita T, Takamatsu H, Kawamura K, et al. A nationwide survey on central nervous system multiple myeloma in Japan: analysis of prognostic and treatment factors that impact survival. Br J Haematol. 2021. PMID: 34318926. doi:10.1111/bjh.17717

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。